Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015054
Filing Date
2024-11-08
Accepted
2024-11-08 16:06:03
Documents
53
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q sngx-20240930x10q.htm   iXBRL 10-Q 1727255
2 EX-31.1 sngx-20240930xex31d1.htm EX-31.1 18453
3 EX-31.2 sngx-20240930xex31d2.htm EX-31.2 19787
4 EX-32.1 sngx-20240930xex32d1.htm EX-32.1 8297
5 EX-32.2 sngx-20240930xex32d2.htm EX-32.2 11175
  Complete submission text file 0001558370-24-015054.txt   6619952

Data Files

Seq Description Document Type Size
6 EX-101.SCH sngx-20240930.xsd EX-101.SCH 36658
7 EX-101.CAL sngx-20240930_cal.xml EX-101.CAL 43062
8 EX-101.DEF sngx-20240930_def.xml EX-101.DEF 196861
9 EX-101.LAB sngx-20240930_lab.xml EX-101.LAB 362495
10 EX-101.PRE sngx-20240930_pre.xml EX-101.PRE 287361
56 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20240930x10q_htm.xml XML 1023451
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14778 | Film No.: 241440529
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)